Pasithea Therapeutics

Pasithea Therapeutics EBIT Margin

The EBIT Margin (Operating Margin) of Pasithea Therapeutics (KTTA) as of Nov 21, 2026 is -3,284.16 %. In the previous year, EBIT Margin (Operating Margin) was -2,587.35 % — a change of 26.93% (lower).

EBIT Margin

-3,284.16 %

YoY

26.93%

Last updated:

EBIT Margin (Operating Margin) of Pasithea Therapeutics is 2023 -3,284.16 % . EBIT Margin (Operating Margin) of Pasithea Therapeutics was 2022 -2,587.35 % . It decreases by 26.93% lower compared to the previous year.

Pasithea Therapeutics's operating (EBIT) margin stands at -3,284.2%, up from -29,925.7% several years earlier.

The Pasithea Therapeutics EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2021
-29,925.73 USD
Jan 1, 2022
-2,587.35 USD
Jan 1, 2023
-3,284.16 USD
The Pasithea Therapeutics EBIT Margin history
YEAREBIT MarginYoY
-3,284.16 %+26.93%
-2,587.35 %-91.35%
-29,925.73 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pasithea Therapeutics Stock analysis

What does Pasithea Therapeutics do? Pasithea Therapeutics Corp. generates revenue through its Therapeutics segment, which develops treatments for Central Nervous System disorders and RASopathies, including its lead product candidate PAS-004, a MEK inhibitor for RASopathies like neurofibromatosis type 1 and Noonan syndrome. The company also offers business support services via its Clinics segment to anti-depression clinics in the United Kingdom and United States. Its therapeutic pipeline includes four programs, with PAS-004 in advanced development and three others in discovery stage. The firm's primary customers are clinics seeking business support services and potential partners for its therapeutic pipeline. The company focuses on CNS disorders and RASopathies, targeting conditions such as neurofibromatosis type 1, Noonan syndrome, and LMNA cardiomyopathy. PAS-004 is designed for multiple indications, including oncology, expanding its potential market reach. The Clinics segment supports anti-depression clinics in the UK and US, providing operational assistance without direct patient care. Revenue streams are derived from therapeutic development partnerships and clinic support services. Pasithea's lead product PAS-004 targets RASopathies and oncology, with a focus on neurofibromatosis type 1 and Noonan syndrome. The Clinics segment serves anti-depression clinics in the UK and US, offering business support services. The company's pipeline includes four programs, with three in early discovery and PAS-004 progressing toward potential commercialization. Revenue is generated through partnerships for therapeutic development and service contracts with clinics. Pasithea Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pasithea Therapeutics stock

EBIT Margin (Operating Margin) of Pasithea Therapeutics is -3,284.16 % in 2023.

EBIT Margin (Operating Margin) of Pasithea Therapeutics changed from -2,587.35 % to -3,284.16 %, representing a 26.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Pasithea Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Pasithea Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Pasithea Therapeutics

All Key Metrics — Pasithea Therapeutics